OnKure Therapeutics (OKUR) Financials

OnKure Therapeutics (NASDAQ: OKUR) remains a development-stage biotech with no revenue, heavy operating losses, and a balance sheet that has been dramatically reshaped by financing activity over the past year.

For Q1 2026, the company reported no revenue and a net loss of $15.2 million, compared with a $13.5 million loss in Q4 2025 and a $15.0 million loss in Q3 2025. Operating expenses were $15.6 million in the quarter, led by R&D expense of $11.7 million and SG&A of $3.9 million. That keeps the business firmly in cash-burn mode, which is typical for clinical-stage biotech companies, but it also means investors are still underwriting future trial progress rather than current earnings power.

One of the most notable developments is the company's liquidity position. Cash and equivalents rose to $192.1 million at March 31, 2026, from $70.3 million at the end of Q3 2025 and $96.7 million at the end of Q1 2025. The increase was driven largely by $146.0 million in common equity issuance during the quarter. That gave OnKure a much stronger cash cushion, even though it came at the cost of dilution.

Historically, the company has shown a steady pattern of quarterly operating losses in the roughly $10 million to $17 million range, with quarterly cash from operations also negative throughout the period reviewed. In Q1 2026, operating cash burn was $12.9 million, a modest improvement versus some prior quarters, but still a significant outflow. Over the last four years, the story has been consistent: meaningful R&D spending, no product revenue, and recurring reliance on outside capital.

The balance sheet now looks much healthier on the surface than it did a year ago. Total assets were $198.7 million in Q1 2026 versus $99.9 million in Q1 2025, while total liabilities were only $14.3 million. That left total common equity at $184.4 million. The company is not burdened by meaningful debt, which reduces financial risk, but equity dilution remains the main tradeoff for shareholders.

• Cash increased sharply to $192.1 million in Q1 2026, giving the company a much stronger liquidity position.
• No debt burden was reported in the latest quarter, which lowers balance sheet risk.
• Operating cash burn improved slightly to $12.9 million in Q1 2026 from $13.5 million in Q2 2025 and $14.0 million in Q1 2025.
• R&D spending remains substantial at $11.7 million, suggesting continued investment in the pipeline.
• The company remains pre-revenue, so valuation still depends on clinical and development milestones rather than sales.
• Quarterly losses remain persistent, with Q1 2026 net loss at $15.2 million.
• Investing cash outflows are minimal, indicating limited capital spending needs beyond research activities.
• Common equity issuance of $146.0 million provided liquidity but likely diluted existing shareholders.
• Accumulated losses continue to grow, with retained earnings at negative $229.4 million in Q1 2026.
• Dependence on external funding remains high, which could pressure the stock if future capital raises are needed.

Bottom line: OKUR’s latest quarter shows a company that successfully strengthened its cash position, but the underlying business remains early stage, unprofitable, and dependent on financing. For retail investors, the key question is whether that enlarged cash runway can support enough clinical progress to create meaningful shareholder value before additional dilution is required.